文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

羟氯喹对住院COVID-19患者14天临床状态的影响:一项随机临床试验

Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01

这项在美国34家医院开展的多中心、盲法、安慰剂对照随机试验,纳入479例因SARS-CoV-2感染住院且伴呼吸道症状的成人患者,比较羟氯喹与安慰剂对14天临床状态的影响。结果显示两组14天 ordinal 临床状态评分无显著差异(aOR 1.02,95%CI 0.73-1.42),12项次要结局亦无显著差异,28天死亡率两组相近。结论不支持对住院成人COVID-19患者使用羟氯喹治疗。

要点

  • 羟氯喹组与安慰剂组14天临床状态评分中位数均为6分(IQR 4-7),aOR 1.02(95%CI 0.73-1.42)。
  • 28天死亡率羟氯喹组10.4%、安慰剂组10.6%,绝对差异-0.2%(95%CI -5.7%至5.3%)。
  • 12项次要结局均无显著组间差异,试验因无效在第四次期中分析时停止。

核心结论

  • 在因COVID-19呼吸道症状住院的成人中,羟氯喹与安慰剂相比未显著改善14天临床状态。
  • 研究结果不支持对住院成人COVID-19患者使用羟氯喹治疗。

研究设计与样本

  • 多中心、盲法、安慰剂对照随机临床试验,在美国34家医院开展。
  • 计划样本量510例,每纳入102例进行期中分析,第四次期中分析因无效停止,实际样本量479例。
  • 纳入2020年4月2日至6月19日因SARS-CoV-2感染伴呼吸道症状住院的成人,末次结局评估于2020年7月17日。
  • 羟氯喹组242例,安慰剂组237例;羟氯喹用法为400 mg每日两次共2剂,随后200 mg每日两次共8剂。

主要发现

  • 14天序贯量表临床状态评分中位数羟氯喹组6分(IQR 4-7)、安慰剂组6分(IQR 4-7),aOR 1.02(95%CI 0.73-1.42)。
  • 12项次要结局均无显著组间差异。
  • 28天死亡:羟氯喹组25/241例(10.4%),安慰剂组25/236例(10.6%),绝对差异-0.2%(95%CI -5.7%至5.3%),aOR 1.07(95%CI 0.54-2.09)。

关键数值与推荐

  • 主要结局为随机化后14天7分类序贯量表临床状态,1分为死亡、7分为出院并能正常活动。
  • 主要结局采用多变量比例优势模型分析,aOR大于1.0提示羟氯喹组结局更优。
  • 433例(90.4%)完成14天主要结局评估,其余采用临床状态插补。

临床怎么用

  • 住院成人COVID-19患者不应以改善14天临床状态为目的使用羟氯喹。
  • 临床决策应依据阴性结果避免无效治疗,减少不必要的药物暴露。

局限性

  • 试验因无效提前停止,实际样本量479例低于计划510例。
  • 14天主要结局评估中90.4%完成,其余采用插补。
  • 研究人群为住院成人,结论不能外推至门诊或非住院患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Data on the efficacy of hydroxychloroquine for the treatment of coronavirus disease 2019 (COVID-19) are needed. OBJECTIVE: To determine whether hydroxychloroquine is an efficacious treatment for adults hospitalized with COVID-19. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter, blinded, placebo-controlled randomized trial conducted at 34 hospitals in the US. Adults hospitalized with respiratory symptoms from severe acute respiratory syndrome coronavirus 2 infection were enrolled between April 2 and June 19, 2020, with the last outcome assessment on July 17, 2020. The planned sample size was 510 patients, with interim analyses planned after every 102 patients were enrolled. The trial was stopped at the fourth interim analysis for futility with a sample size of 479 patients. INTERVENTIONS: Patients were randomly assigned to hydroxychloroquine (400 mg twice daily for 2 doses, then 200 mg twice daily for 8 doses) (n = 242) or placebo (n = 237). MAIN OUTCOMES AND MEASURES: The primary outcome was clinical status 14 days after randomization as assessed with a 7-category ordinal scale ranging from 1 (death) to 7 (discharged from the hospital and able to perform normal activities). The primary outcome was analyzed with a multivariable proportional odds model, with an adjusted odds ratio (aOR) greater than 1.0 indicating more favorable outcomes with hydroxychloroquine than placebo. The trial included 12 secondary outcomes, including 28-day mortality. RESULTS: Among 479 patients who were randomized (median age, 57 years; 44.3% female; 37.2% Hispanic/Latinx; 23.4% Black; 20.1% in the intensive care unit; 46.8% receiving supplemental oxygen without positive pressure; 11.5% receiving noninvasive ventilation or nasal high-flow oxygen; and 6.7% receiving invasive mechanical ventilation or extracorporeal membrane oxygenation), 433 (90.4%) completed the primary outcome assessment at 14 days and the remainder had clinical status imputed. The median duration of symptoms prior to randomization was 5 days (interquartile range [IQR], 3 to 7 days). Clinical status on the ordinal outcome scale at 14 days did not significantly differ between the hydroxychloroquine and placebo groups (median [IQR] score, 6 [4-7] vs 6 [4-7]; aOR, 1.02 [95% CI, 0.73 to 1.42]). None of the 12 secondary outcomes were significantly different between groups. At 28 days after randomization, 25 of 241 patients (10.4%) in the hydroxychloroquine group and 25 of 236 (10.6%) in the placebo group had died (absolute difference, -0.2% [95% CI, -5.7% to 5.3%]; aOR, 1.07 [95% CI, 0.54 to 2.09]). CONCLUSIONS AND RELEVANCE: Among adults hospitalized with respiratory illness from COVID-19, treatment with hydroxychloroquine, compared with placebo, did not significantly improve clinical status at day 14. These findings do not support the use of hydroxychloroquine for treatment of COVID-19 among hospitalized adults. TRIAL REGISTRATION: ClinicalTrials.gov: NCT04332991.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Self WH, Semler MW, Leither LM, et al. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2020. PMID: 33165621. doi:10.1001/jama.2020.22240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。